Biovica International AB logo

BIOVIC B - Biovica International AB Share Price

SEK36.4 -1.0  -2.7%

Last Trade - 03/03/21

Sector
Healthcare
Size
Small Cap
Market Cap £90.5m
Enterprise Value £76.8m
Revenue £37.6k
Position in Universe 913th / 1857
Bullish
Bearish
Unlock BIOVIC B Revenue
Momentum
Relative Strength (%)
1m -15.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Apr 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.46 2.43 0.63 2.72 3.01 1.67 2.00 39.0 +29.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 October 2020, BiovicaInternational AB revenues decreased 76% to SEK384K. Netloss applicable to common stockholders increased 38% toSEK16.6M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Higher net loss reflects Personnel costsincrease of 33% to SEK12.2M (expense), Other ExternalExpenses increase of 30% to SEK7.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BIOVIC B
Graphical History

Revenue

BIOVIC B Revenue Unlock BIOVIC B Revenue

Net Income

BIOVIC B Net Income Unlock BIOVIC B Revenue

Normalised EPS

BIOVIC B Normalised EPS Unlock BIOVIC B Revenue

PE Ratio Range

BIOVIC B PE Ratio Range Unlock BIOVIC B Revenue

Dividend Yield Range

BIOVIC B Dividend Yield Range Unlock BIOVIC B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIOVIC B EPS Forecasts Unlock BIOVIC B Revenue
Profile Summary

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Directors
Last Annual April 30th, 2020
Last Interim October 31st, 2020
Public Since March 29, 2017
No. of Shareholders: n/a
No. of Employees: 21
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 28,273,372
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIOVIC B Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIOVIC B
Upcoming Events for BIOVIC B
Frequently Asked Questions for Biovica International AB
What is the Biovica International AB share price?

As of 03/03/21, shares in Biovica International AB are trading at SEK36.4, giving the company a market capitalisation of £90.5m. This share price information is delayed by 15 minutes.

How has the Biovica International AB share price performed this year?

Shares in Biovica International AB are currently trading at SEK36.4 and the price has moved by 0.153k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biovica International AB price has moved by 0.137k% over the past year.

What are the analyst and broker recommendations for Biovica International AB?

Of the analysts with advisory recommendations for Biovica International AB, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biovica International AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biovica International AB next release its financial results?

Biovica International AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-10-31
What is the Biovica International AB dividend yield?

Biovica International AB does not currently pay a dividend.

Does Biovica International AB pay a dividend?

Biovica International AB does not currently pay a dividend.

When does Biovica International AB next pay dividends?

Biovica International AB does not currently pay a dividend.

How do I buy Biovica International AB shares?

To buy shares in Biovica International AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biovica International AB?

Shares in Biovica International AB are currently trading at SEK36.4, giving the company a market capitalisation of £90.5m.

Where are Biovica International AB shares listed? Where are Biovica International AB shares listed?

Here are the trading details for Biovica International AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: BIOVIC B
What kind of share is Biovica International AB?

Based on an overall assessment of its quality, value and momentum, Biovica International AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biovica International AB share price forecast 2021?

Shares in Biovica International AB are currently priced at SEK36.4. At that level they are trading at 35.83% premium to the analyst consensus target price of 0.00.

Analysts covering Biovica International AB currently have a consensus Earnings Per Share (EPS) forecast of -1.35 for the next financial year.

How can I tell whether the Biovica International AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biovica International AB. Over the past six months, the relative strength of its shares against the market has been 6.64%. At the current price of SEK36.4, shares in Biovica International AB are trading at 7.32% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biovica International AB PE Ratio?

We were not able to find PE ratio data for Biovica International AB.

Who are the key directors of Biovica International AB?

Biovica International AB's management team is headed by:

Jarl Jungnelius - DRC
Maria Holmlund - DRC
Jesper Soderqvist - DRC
Anders Rylander - CEO
Cecilia Driving - CFO
Mattias Bergqvist - VPR
Christina Andersson - COO
Johanna Faris - OTH
Gabriel Sack - VBD
Lars Holmqvist - CHM
Henrik Osvald - DRC
Otti Gref - OTH
Henrik Winther - SVP
Who are the major shareholders of Biovica International AB?

Here are the top five shareholders of Biovica International AB based on the size of their shareholding:

Coeli Asset Management Investment Advisor/Hedge Fund
Percentage owned: 6.52% (1.42m shares)
Coeli SICAV II Absolute European Equity Mutual Fund
Percentage owned: 4.25% (926k shares)
Coeli SICAV II - European Opportunities Mutual Fund
Percentage owned: 2.27% (494k shares)
Deka Investment GmbH Investment Advisor/Hedge Fund
Percentage owned: 1.82% (398k shares)
Deka-UnternehmerStrategie Europa Mutual Fund
Percentage owned: 1.32% (289k shares)
Similar to BIOVIC B
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.